Journal of Clinical Oncology, Vol 8, 1399-1401, Copyright © 1990 by American Society of Clinical Oncology

ARTICLES

Ifosfamide neurotoxicity is related to previous cisplatin treatment for pediatric solid tumors

CB Pratt, MP Goren, WH Meyer, B Singh and RK Dodge
Departments of Hematology-Oncology, St Jude Children's Research Hospital, Memphis, TN 38101-0318.

Neurotoxicity developed in 22 of 97 children and adolescents with malignant solid tumors treated within a phase II ifosfamide protocol. The occurrence of neurotoxicity was related to previous cumulative dosages of cisplatin. One third of the patients who had received more than 600 mg/m2 of cisplatin developed this complication. The relative risk increased 3.2-fold with previous cisplatin dosages above 301 to 600 mg/m2, and 4.1-fold with dosages of 601 to 1,340 mg/m2. The increased risk of neurotoxicity in patients who had received more than 600 mg/m2 of cisplatin may be related to either a decreased clearance of ifosfamide itself or of the drug's active metabolites.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				K. C. Oeffinger and M. M. Hudson Long-term Complications Following Childhood and Adolescent Cancer: Foundations for Providing Risk-based Health Care for Survivors CA Cancer J Clin, July 1, 2004; 54(4): 208 - 236. [Abstract] [Full Text] [PDF]

				M. S H Lam and R. J Ignoffo A guide to clinically relevant drug interactions in oncology Journal of Oncology Pharmacy Practice, June 1, 2003; 9(2-3): 45 - 85. [Abstract] [PDF]

				W. J. Wengs, D. Talwar, and J. Bernard Ifosfamide-Induced Nonconvulsive Status Epilepticus Arch Neurol, October 1, 1993; 50(10): 1104 - 1105. [Abstract] [PDF]